Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-26T09:33:34.489Z Has data issue: false hasContentIssue false
  • English
  • Français

Currents in Contemporary Ethics

For Asians Only? The Perils of Ancestry-Based Drug Prescribing

Published online by Cambridge University Press:  01 January 2021

Perry W. Payne Jr.
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
JLME Column
Information
Journal of Law, Medicine & Ethics , Volume 36 , Issue 3 , Fall 2008 , pp. 585 - 588
Copyright
Copyright © American Society of Law, Medicine and Ethics 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abrahams, E., Ginsburg, G. S., and Silver, M., “The Personalized Medicine Coalition: Goals and Strategies,” American Journal of PharmacoGenomics 5, no. 6 (2005): 345–355; Lewis, L. D., “Personalized Drug Therapy; The Genome, The Chip and the Physician,” British Journal of Clinical Pharmacology 60, no. 1 (2005): 1–4.CrossRefGoogle Scholar
U.S. Food and Drug Administration Center for Drug Evaluation and Research, Information for Healthcare Professionals: Carbamazepine (Marketed as Carbatrol, Equetro, Tegretol, and Generics) - FDA Alert, available at <http://www.fda.gov/cder/drug/InfoSheets/HCP/carbamazepineHCP.htm> (last visited June 23, 2008) [hereinafter cited as USDA); Dooren, J. C. and Goldstein, J., “Epilepsy Drug to Get Stronger Warning,” Wall Street Journal (Eastern Edition), December 13, 2007, at D4.+(last+visited+June+23,+2008)+[hereinafter+cited+as+USDA);+Dooren,+J.+C.+and+Goldstein,+J.,+“Epilepsy+Drug+to+Get+Stronger+Warning,”+Wall+Street+Journal+(Eastern+Edition),+December+13,+2007,+at+D4.>Google Scholar
Id. (USDA).Google Scholar
Id.Google Scholar
Alfirevic, A., Jorgensen, A. L., Williamson, P. R., Chadwick, D. W., Park, B. K., and Pirmohamed, M., “HLA-B Locus in Caucasian Patients with Carbamazepine Hypersensitivity,” Pharmacogenomics 7, no. 6 (2006): 813–818; Hung, S. I., Chung, W. H., Jee, S. H., Chen, W. C., Chang, Y. T., Lee, W. R., Hu, S. L., Wu, M. T., Chen, G. S., Wong, T. W., Hsiao, P. F., Chen, W. H., Shih, H. Y., Fang, W. H., Wei, C. Y., Lou, Y. H., Huang, Y. L., Lin, J. J., and Chen, Y. T., “Genetic Susceptibility to Carbamazepine-Induced Cutaneous Adverse Drug Reactions,” Pharmacogenetics and Genomics 16, no. 4 (2006): 297–306; Lonjou, C., Thomas, L., Borot, N., Ledger, N., de Toma, C., LeLouet, H., Graf, E., Schumacher, M., Hovnanian, A., Mockenhaupt, M., and Roujeau, J. C., “A Marker for Stevens-Johnson Syndrome…: Ethnicity Matters,” Pharmacogenomics Journal 6, no. 4 (2006): 265–268; Man, C. B. L., Kwan, P., Baum, L., Yu, E., Lau, K. M., Cheng, A. S. H., and Ng, M. H. L., “Association between HLA-B*1502 Allele and Antiepileptic Drug-Induced Cutaneous Reactions in Han Chinese,” Epilepsia 48, no. 5 (2007): 1015–1018; Chung, W. H., Hung, S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C., Wu, J. Y., and Chen, Y. T., “Medical Genetics: A Marker for Stevens-Johnson Syndrome,” Nature 428, no. 6982 (2004): 486.CrossRefGoogle Scholar
See USDA, supra note 2.Google Scholar
Id.Google Scholar
See generally Veregin, H., ed., Goode's Atlas of Asia (New Jersey: John Wiley & Sons, 2004).Google Scholar
See USDA, supra note 2.Google Scholar
Id.Google Scholar
U.S. Food and Drug Administration, FDA News, FDA Approves BiDil Heart Failure Drug for Black Patients, available at <http://www.fda.gov/bbs/topics/news/2005/new01190.html> (last visited June 23, 2008).+(last+visited+June+23,+2008).>Google Scholar
Stewart, A., “Heart Drug's Racial Focus Proves a Liability Rather Than an Asset,” The Star Ledger, May 31, 2008, available at <http://www.nj.com/business/index.ssf/2008/05/heart_drugs_racial_focus_prove.html> (last visited June 23, 2008); Kahn, J., “How a Drug Becomes ‘Ethnic’: Law, Commerce, and the Production of Racial Categories in Medicine,” Yale Journal of Health Policy Law 4, no. 1 (2004): 1–46; Armstrong, D., “Home and Family: NitroMed Halts Sale of Drug,” Wall Street Journal (Eastern Edition), January 16, 2008, at D3.Google Scholar